RNA
Atrium Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.11
P/S
11.20
EV/EBITDA
0.76
DCF Value
$-21.08
FCF Yield
-20.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-412.6%
Net Margin
-411.9%
ROE
-37.0%
ROA
-27.5%
ROIC
-31.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $859.0K | $-48.1M | $0.00 |
| FY 2025 | $18.6M | $-76.7M | $-4.48 |
| Q3 2025 | $12.5M | $-174.4M | $-1.27 |
| Q2 2025 | $3.8M | $-157.3M | $-1.21 |
Analyst Ratings
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.00
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.